Treatment for hepatitis B

BMJ (Online)

Volumn 340, Issue 7737, 2010, Pages 87-91

  Cooke, Graham S ^a,b   Main, Janice ^a   Thursz, Mark R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

AFRICA; ANTIGEN DETECTION; DRUG EFFICACY; ECHOGRAPHY; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDLINE; MIXED INFECTION; MORBIDITY; MORTALITY; NEPHROTOXICITY; OCCUPATIONAL EXPOSURE; PATIENT COMPLIANCE; PATIENT REFERRAL; PHOSPHATE BLOOD LEVEL; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEXUAL INTERCOURSE; SIDE EFFECT; SOUTHEAST ASIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION;

ACUTE DISEASE; ANTIVIRAL AGENTS; BIOPSY; FEMALE; FORECASTING; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; PATIENT SELECTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS;

EID: 74949135450     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b5429     Document Type: Review

References (34)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.
3. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepatol 2009;16:94-103.
4. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989;1:889-93.
5. Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E. The prevalence of hepatitis B infection in adults in England and Wales. Epidemiol Infect 1999;122:133-8.
6. Ganem D Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-29.
7. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
8. Thun MJ, Delancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2009. Nov 24 PMID:19934210.
9. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
10. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760-7.
11. Centers for Disease Control and Prevention. Recommendations for the identification and public-health management of persons with chronic hepatitis B virus infection. MMWR 2008;57.
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
13. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
14. Sung JJ, Chan HL, Wong ML, Tse CH, Yuen SC, Tam JS, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepatol 2002;9:229-34.
15. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
16. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-47.
17. Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis 2008;12:883-900.
18. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
19. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.
20. Lai CL, Yuen MF. Chronic hepatitis B - new goals, new treatment. N Engl J Med 2008;359:2488-91.
21. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009;49(suppl 5):103-11S.
22. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
23. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411-6.
24. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51.
25. National Institute for Health and Clinical Guidance. Entecavir for the treatment of chronic hepatitis B. (Technology appraisal 153.) 2008. http://guidance.nice.org.uk/TA153
26. National Institute for Health and Clinical Guidance. Tenofovir for the treatment of chronic hepatitis B. (Technology appraisal 173.) 2008. http://guidance.nice.org.uk/TA173
27. National Institute for Health and Clinical Guidance. Telbivudine for the treatment of chronic hepatitis B. (Technology appraisal 154.) 2008. http://guidance.nice.org.uk/TA154
28. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49(suppl 5):S185-95.
29. Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV cohort study. Antivir Ther 2008;13:1077-82.
30. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 2002;37:366-9.
31. Reshef R, Sbeit W, Tur-Kaspa R. Lamivudine in the treatment of acute hepatitis B. N Engl J Med 2000;343:1123-4.
32. Lessells RJ, Main J, Cooke GS. HIV and hepatitis B co-infection in Africa: implications for the public health approach to ART. Lancet Infect Dis 2008;8:210-1.
33. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
34. Thursz M, Cooke GS, Hall AJ. Hepatitis B treatment in resource-poor settings: time for action. Trop Med Int Health 2009;15(1):2-4.